Neurocrine Biosciences, Inc.
NASDAQNeurocrine Biosciences is trading in a peculiar gap: short sellers are exiting at speed, yet options traders remain the most defensively positioned they have been in months — a split that tells two different stories about who still believes the post-earnings damage is done. The short-covering trend is the week's most striking data point. Short interest collapsed 19% in a single…
NBIX short interest surges 21.8% in one week to 5.3% of float, as stock rallies ahead of earnings.
Neurocrine Biosciences is trading in a peculiar gap: short sellers are exiting at speed, yet options traders remain the most defensively positioned they have been in months — a split that tells two different stories…
Options positioning on NBIX has flipped sharply since earnings. The put-call ratio hit 1.00 on August 6 — the highest in three months and a z-score of 3.3 standard deviations above the 20-day mean of 0.85. That is a…
Snapshot as of 20 Sept 2026
Neurocrine Biosciences has taken a sharp hit after its Q2 print, falling 10.2% on Friday to $166.58 — yet the Street has responded not by retreating, but by lifting targets almost across the board. The earnings…
Neurocrine Biosciences heads into tonight's Q2 earnings report with analysts raising targets, the stock near a multi-month high, and short sellers in retreat — a setup where the bull case is already partly priced…
NBIX heads into the week with an interesting split: Goldman Sachs reinstated coverage with a Buy and a $213 target on the same day the stock fell nearly 4%. The analyst activity has been firmly bullish. Goldman's…
NBIX closed the week at $135.06, up 5.4% in five sessions, as a clean Q1 earnings release on May 5 triggered a wave of analyst target increases the following morning — a rare show of broad post-results conviction. The…
Neurocrine Biosciences heads into its May 5 Q1 results with a notable and accelerating build in short positions — the most distinctive feature of the current setup. Short interest has climbed sharply over the past…
Neurocrine Biosciences heads into its May 1 Q1 results with short sellers meaningfully more aggressive than they were just a month ago — and options traders turning cautious on the day before the release. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NBIX — free to start on ORTEX.
Sign up for free →Open NBIX on ORTEX